A survey of medical researchers indicates poor awareness of research data management processes and a role for data librarians.

BACKGROUND: The European Parliament's directive on open data indicates the direction to follow for all public institutions in Europe. The portal Polish Platform of Medical Research (PPM) required more information about researcher attitudes and training requirements for strategic planning. OBJECTIVES: The aim was to assess (1) the status of knowledge about research data management among medical researchers in Poland, and (2) their attitudes towards data sharing. This knowledge may help to inform a training program and adapt PPM to the requirements of researchers. METHODS: The authors circulated an online survey and received responses from 603 researchers representing medical sciences and related disciplines. The survey was conducted in 2019 at seven Polish medical universities and at the Nofer Institute of Occupational Medicine. Analysis used descriptive statistics. RESULTS: Data sharing was not widespread (55.7% only shared with their research team, 9.8% had shared data on an open access basis). Many cited possible benefits of research data sharing but were concerned about drawbacks (e.g. fraud, plagiarism). DISCUSSION: Polish medical scientists, like many researchers, are not aware of the processes required for safe data preparation for sharing. Academic libraries should develop roles for data librarians to help train researchers. CONCLUSION: Fears about the dangers of data sharing need to be overcome before researchers are willing to share their own research data.

New therapeutic approaches in the treatment of node-positive cervical cancer patients based on molecular targets: a systematic review.

Cervical uterine cancer is the second most frequent female cancer worldwide and a substantial burden for low-income societies and the patients themselves. Understanding the molecular mechanisms of metastasis permits the development of therapies that limit tumor progression, as well as providing health and social benefits. Pathomorphology is still the basis of research and a reference standard for molecular analysis. The aim of our study was to research and critically evaluate clinical trials that use new oncological approaches for node-positive cervical cancer to gain an insight into the molecular mechanisms of tumor metastasis. INCLUSION CRITERIA: node-positive disease at baseline; at least a first phase clinical study comprising adult female patients; novel clinical approach (e.g., radiotherapy, immunotherapy, targeted therapy, vaccines, radiosurgery); histologic measurement of treatment efficacy (preferably lymph node ultrastaging); and publications in English language only. INFORMATION SOURCES: US Clinical trials registry, EU Clinical trials register, ISRCTN registry, and Ovid, EBSCO and Cochrane Collaboration databases. Access dates: from January 2010 to April 2018. EXCLUSIONS: Abstracts that did not meet the inclusion criteria or with unreliable data. We collected complete data (e.g., the entire publication associated with included abstracts, heterogeneity examination of individual studies, and validity measurement of the statistical methods used). Results were analyzed in relation to the most recent understanding of the pathogenesis of cervical cancer metastasis. We proposed a possible direction for drug treatment of epithelial tumors based on the mechanisms of metastasis.

Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi.

Malignant melanoma is notoriously refractive to therapy and resistant to apoptosis. This may reflect the downregulation of Apaf-1, an important mediator of mitochondrial-dependent apoptosis, observed in vitro in melanoma cell lines and by immunohistochemistry for Apaf-1 protein in histological samples of primary and metastatic melanomas. Although it has been suggested that loss of Apaf-1 expression may be an indicator of malignant transformation in melanoma, previous studies on Apaf-1 expression in benign pigmented nevi were performed without reference to their histologic type. Here we have evaluated the expression of Apaf-1 mRNA by fluorescence in situ hybridization and of Apaf-1 protein by immunohistochemistry in a large panel of human melanomas and in eight types of pigmented nevi, considered potential precursors for cutaneous melanoma. We observe a strong negative correlation between melanoma progression assessed according to Clark classification and the expression of Apaf-1. A significant decrease in Apaf-1 expression was observed between Clark II and Clark III lesions, the stages usually associated with a transition from horizontal to vertical growth phase of melanoma. There was also statistically significant difference in Apaf-1 mRNA expression between melanomas of Breslow thickness <1 mm and >4 mm. No Apaf-1 expression could be detected in lymph node melanoma metastases. These results suggest that Apaf-1 expression may become a prognostic marker for progress of human cutaneous melanoma and further support the notion that loss of Apaf-1 may be an important contributory factor in the development of the disease.